Q Hu, X Tang, F Liu, D Liu… - Therapeutic advances in …, 2023 - journals.sagepub.com
Background: The application of vedolizumab (VDZ) subcutaneous (SC) formulation has
brought more convenience and hope to patients with moderate-to-severe inflammatory …